[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 81, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1037500, "exercisedValue": 0, "unexercisedValue": 9922011}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 55, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 59, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Whitmire", "title": "Vice President of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Dobek", "age": 34, "title": "Principal Accounting Officer & VP of Accounting", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tommy  Diraimondo Ph.D.", "age": 38, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 40, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachariah  McIver D.O., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 30.75, "open": 30.65, "dayLow": 30.43, "dayHigh": 31.47, "regularMarketPreviousClose": 30.75, "regularMarketOpen": 30.65, "regularMarketDayLow": 30.43, "regularMarketDayHigh": 31.47, "payoutRatio": 0.0, "beta": 3.223, "forwardPE": -19.15, "volume": 642976, "regularMarketVolume": 642976, "averageVolume": 991559, "averageVolume10days": 1087740, "averageDailyVolume10Day": 1087740, "bid": 30.44, "ask": 30.86, "bidSize": 2, "askSize": 1, "marketCap": 1810980224, "fiftyTwoWeekLow": 29.63, "fiftyTwoWeekHigh": 71.71, "priceToSalesTrailing12Months": 171.04082, "fiftyDayAverage": 42.6096, "twoHundredDayAverage": 46.030075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 808833728, "profitMargins": 0.0, "floatShares": 38114545, "sharesOutstanding": 59105100, "sharesShort": 9091177, "sharesShortPriorMonth": 8552992, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.1539, "heldPercentInsiders": 0.07048, "heldPercentInstitutions": 1.13743, "shortRatio": 9.48, "shortPercentOfFloat": 0.2731, "impliedSharesOutstanding": 59105100, "bookValue": 17.316, "priceToBook": 1.7694618, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -68994000, "trailingEps": -1.28, "forwardEps": -1.6, "enterpriseToRevenue": 76.392, "enterpriseToEbitda": -8.357, "52WeekChange": -0.23067302, "SandP52WeekChange": 0.121255875, "quoteType": "EQUITY", "currentPrice": 30.64, "targetHighPrice": 200.0, "targetLowPrice": 25.0, "targetMeanPrice": 87.84615, "targetMedianPrice": 91.0, "recommendationMean": 1.21429, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 13, "totalCash": 1025172992, "totalCashPerShare": 17.345, "ebitda": -96787000, "totalDebt": 23025000, "quickRatio": 59.027, "currentRatio": 59.205, "totalRevenue": 10588000, "debtToEquity": 2.251, "revenuePerShare": 0.197, "returnOnAssets": -0.08569, "returnOnEquity": -0.100930005, "grossProfits": -57800000, "freeCashflow": -26144376, "operatingCashflow": -43814000, "revenueGrowth": -1.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -9.33576, "financialCurrency": "USD", "symbol": "JANX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -0.35772556, "regularMarketPrice": 30.64, "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "cryptoTradeable": false, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1741394983, "regularMarketTime": 1741381202, "exchange": "NGM", "messageBoardId": "finmb_676965261", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "postMarketChangePercent": 4.40601, "postMarketPrice": 31.99, "postMarketChange": 1.35, "regularMarketChange": -0.11000061, "regularMarketDayRange": "30.43 - 31.47", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 991559, "fiftyTwoWeekLowChange": 1.0100002, "fiftyTwoWeekLowChangePercent": 0.034087084, "fiftyTwoWeekRange": "29.63 - 71.71", "fiftyTwoWeekHighChange": -41.07, "fiftyTwoWeekHighChangePercent": -0.57272345, "fiftyTwoWeekChangePercent": -23.0673, "earningsTimestamp": 1740690060, "earningsTimestampStart": 1746475200, "earningsTimestampEnd": 1746907200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.28, "epsForward": -1.6, "epsCurrentYear": -2.04444, "priceEpsCurrentYear": -14.986989, "fiftyDayAverageChange": -11.969601, "fiftyDayAverageChangePercent": -0.28091323, "twoHundredDayAverageChange": -15.390076, "twoHundredDayAverageChangePercent": -0.33434826, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-11", "averageAnalystRating": "1.2 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623418200000, "displayName": "Janux Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]